Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29185815 | 0.82 | MEN1 (0.38) | CYP3A4ALDH1A1MEN1ALOX15KMT2A | |
| SCHEMBL29185841 | 0.82 | MEN1 (0.38) | CYP3A4ALDH1A1MEN1ALOX15KMT2A | |
| SCHEMBL20819487 | 0.75 | CYP3A4 (0.52) | CYP3A4ALDH1A1LMNATDP1MEN1 | |
| SCHEMBL113867 | 0.75 | CYP3A4 (0.52) | CYP3A4ALDH1A1LMNATDP1MEN1 | |
| SCHEMBL29446627 | 0.73 | CYP3A4 (0.55) | CYP3A4ALDH1A1LMNATDP1MEN1 | |
| SCHEMBL10834300 | 0.72 | LMNA (0.52) | CYP3A4ALDH1A1LMNATDP1MEN1 | |
| SCHEMBL8306636 | 0.71 | CYP3A4 (0.40) | CYP3A4ALDH1A1LMNATDP1MEN1 | |
| SCHEMBL5322857 | 0.70 | ALDH1A1 (0.43) | CYP3A4ALDH1A1LMNATDP1MEN1 | |
| SCHEMBL19812427 | 0.70 | ALDH1A1 (0.43) | CYP3A4ALDH1A1LMNATDP1MEN1 | |
| SCHEMBL11843905 | 0.70 | ALDH1A1 (0.51) | CYP3A4ALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-4355728-A1 | FRAGRANCE COMPOUNDS | Givaudan SA (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-117500783-A | Perfume compounds | 奇华顿股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022261956-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263605-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | FASN, FAAH2, FADS2 | CYP3A4 133/4885ALDH1A1 27/4885LMNA 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.